Page 79 - Merck Sharp News Today

DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ — PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of...

Outh Africa’s medicines regulator recently approved a branded version of molnupiravir, a new Covid-19 treatment. But when it comes to affordability and access to the medication, the country’s private sector is getting the raw end of the deal.

South Africa’s medicines regulator recently approved a branded version of molnupiravir, a new Covid treatment.

Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or...

Investegate announcements from NetScientific PLC, PDS Announces Preliminary Safety Data on PDS0101

Increase in prevalence of benign prostatic hyperplasia, rise in awareness toward urological disorders, and surge in healthcare expenditure worldwide drive the growth of the global benign prostatic

/PRNewswire/ -- Allied Market Research published a report, titled, "Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class (Alpha Blocker,...

SAN FRANCISCO — Certain immune cell-related parameters appeared associated with efficacy of immune checkpoint inhibitors among patients with advanced or metastatic clear cell renal cell carcinoma, according to study results.“These immune cell parameters may represent novel predictive biomarkers for the response to nivolumab and/or nivolumab plus ipilimumab therapy in clear cell [renal

This prospective cohort study compares the risk of posttraumatic stress disorder among family members of patients with COVID-19-related acute respiratory distre

Adding olaparib to first-line abiraterone improved radiographic progression-free survival in metastatic castration-resistant prostate cancer.